June 28, 2019 07:27 AM EDTUpdated July 3, 07:00 AM

Puretech-backed Karuna makes Nasdaq debut with $89M IPO

Natalie Grover

Reporter

Betting on the potential of two older drugs to fight Alzheimer’s and schizophrenia — Boston-based Karuna Therapeutics has priced its upsized initial public offering in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Puretech-backed Karuna makes Nasdaq debut with $89M IPO

Natalie Grover

Reporter

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

US drugs rely heavily on ingredients made overseas, new report shows

Biotech seed rounds sink to lowest level in years as industry slump drags on

Pharma's wins and losses in Trump's sprawling executive order on drug prices

Eli Lilly reports first Phase 3 data for oral GLP-1, posting a win in diabetes

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

Puretech-backed Karuna makes Nas­daq de­but with $89M IPO

Reporter

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

Puretech-backed Karuna makes Nasdaq debut with $89M IPO